Literature DB >> 25938284

The impact of smoke exposure on the clinical phenotype of alpha-1 antitrypsin deficiency in Ireland: exploiting a national registry to understand a rare disease.

M Emmet O'Brien1, Kevin Pennycooke, Tomás P Carroll, Jonathan Shum, Laura T Fee, Catherine O'Connor, P Mark Logan, Emer P Reeves, Noel G McElvaney.   

Abstract

Individuals with Alpha-1 antitrypsin deficiency (AATD) have mutations in the SERPINA1 gene causing genetic susceptibility to early onset lung and liver disease that may result in premature death. Environmental interactions have a significant impact in determining the disease phenotype and outcome in AATD. The aim of this study was to assess the impact of smoke exposure on the clinical phenotype of AATD in Ireland. Clinical demographics and available thoracic computerised tomography (CT) imaging were detected from 139 PiZZ individuals identified from the Irish National AATD Registry. Clinical information was collected by questionnaire. Data was analysed to assess AATD disease severity and evaluate predictors of clinical phenotype. Questionnaires were collected from 107/139 (77%) and thoracic CT evaluation was available in 72/107 (67.2%). 74% of respondents had severe Chronic Obstructive Pulmonary Disease (COPD) (GOLD stage C or D). Cigarette smoking was the greatest predictor of impairment in FEV1 and DLCO (%predicted) and the extent of emphysema correlated most significantly with DLCO. Interestingly the rate of FEV1 decline was similar in ex-smokers when compared to never-smokers. Passive smoke exposure in childhood resulted in a greater total pack-year smoking history. Radiological evidence of bronchiectasis was a common finding and associated with increasing age. The Irish National AATD Registry facilitates clinical and basic science research of this condition in Ireland. This study illustrates the detrimental effect of smoke exposure on the clinical phenotype of AATD in Ireland and the benefit of immediate smoking cessation at any stage of lung disease.

Entities:  

Keywords:  SERPINA1; occupational exposure; passive smoke; phenotype; questionnaire; radiology

Mesh:

Substances:

Year:  2015        PMID: 25938284     DOI: 10.3109/15412555.2015.1021913

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  7 in total

Review 1.  Why is Disease Penetration so Variable in Alpha-1 Antitrypsin Deficiency? The Contribution of Environmental Factors.

Authors:  Madhu Rangaraju; Alice M Turner
Journal:  Chronic Obstr Pulm Dis       Date:  2020-07

Review 2.  Advances in managing COPD related to α1 -antitrypsin deficiency: An under-recognized genetic disorder.

Authors:  Timothy J Craig; Maria Paula Henao
Journal:  Allergy       Date:  2018-07-26       Impact factor: 13.146

Review 3.  Update on α1-antitrypsin deficiency.

Authors:  Ilaria Ferrarotti; Stefania Ottaviani; Annalisa De Silvestri; Angelo G Corsico
Journal:  Breathe (Sheff)       Date:  2018-06

Review 4.  A Review of Alpha-1 Antitrypsin Binding Partners for Immune Regulation and Potential Therapeutic Application.

Authors:  Michael E O'Brien; Grace Murray; Debananda Gogoi; Azeez Yusuf; Cormac McCarthy; Mark R Wormald; Michelle Casey; Claudie Gabillard-Lefort; Noel G McElvaney; Emer P Reeves
Journal:  Int J Mol Sci       Date:  2022-02-23       Impact factor: 5.923

5.  A stacking ensemble machine learning model to predict alpha-1 antitrypsin deficiency-associated liver disease clinical outcomes based on UK Biobank data.

Authors:  Linxi Meng; Will Treem; Graham A Heap; Jingjing Chen
Journal:  Sci Rep       Date:  2022-10-11       Impact factor: 4.996

Review 6.  Alpha-1 antitrypsin deficiency: outstanding questions and future directions.

Authors:  María Torres-Durán; José Luis Lopez-Campos; Miriam Barrecheguren; Marc Miravitlles; Beatriz Martinez-Delgado; Silvia Castillo; Amparo Escribano; Adolfo Baloira; María Mercedes Navarro-Garcia; Daniel Pellicer; Lucía Bañuls; María Magallón; Francisco Casas; Francisco Dasí
Journal:  Orphanet J Rare Dis       Date:  2018-07-11       Impact factor: 4.123

7.  Activation of complement component 3 is associated with airways disease and pulmonary emphysema in alpha-1 antitrypsin deficiency.

Authors:  Michael E O'Brien; Laura Fee; Niall Browne; Tomás P Carroll; Paula Meleady; Michael Henry; Karen McQuillan; Mark P Murphy; Mark Logan; Cormac McCarthy; Oliver J McElvaney; Emer P Reeves; Noel G McElvaney
Journal:  Thorax       Date:  2020-01-20       Impact factor: 9.139

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.